Translating Research Into Practice (TRIP)

home / series / translating-research-into-practice-trip
personality disorders

Assessing the Effectiveness of Treatments of Personality Disorders in the Community

Anvesh Jalasutram, MD;Ayse Coskun, MD;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP
December 13th 2024

Patients with personality disorders would benefit from therapy regardless of modality, duration, or intensity.

psychosis

The Safety of Psychostimulants or Atomoxetine for Patients With Psychotic Disorders

Nicholas Distefano, MD;Bransen Guild, DO;David Wilton, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP
August 14th 2024

Evidence indicates that children and adolescents with ADHD have a more than 4-fold increased risk of schizophrenia spectrum and other psychotic disorders in adulthood compared with the general population.

A study assessed the associations between the use of ADHD medications and CVD over the course of 14 years. Here's what the investigators found.

Longitudinal Study Looks at Risk of Cardiovascular Disease With Long-Term ADHD Medication Use

Masha Impallaria, MD;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP
May 25th 2024

A study assessed the associations between the use of ADHD medications and CVD over the course of 14 years. Here's what the investigators found.

Recent research investigated the benefits and risks of augmentation compared with switching strategies for TRD in older adults.

Treatment-Resistant Geriatric Depression: Augmenting or Switching an Antidepressant

Lalangi Marasinghe, MD;Anvesh Jalasutram, MD;Phil Ryan, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP
April 17th 2024

Recent research investigated the benefits and risks of augmentation compared with switching strategies for TRD in older adults.

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease

Meagan Kubista, MD;Grethel Perez Meek, DO;Kyle Sramek, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP
February 20th 2024

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

How efficacious is brexpiprazole as a treatment for agitation associated with Alzheimer disease?

Exploring the Role of Brexpiprazole in Alzheimer Dementia Agitation

Justin Allen, MD;Albert Dickan, MD;Jesse Woo, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP
January 16th 2024

How efficacious is brexpiprazole as a treatment for agitation associated with Alzheimer disease?

© 2024 MJH Life Sciences

All rights reserved.